Literature DB >> 26241432

Care of the Pregnant Patient With Inflammatory Bowel Disease.

Uma Mahadevan1, Rebecca Matro.   

Abstract

Inflammatory bowel disease affects women in their peak reproductive years. Patients and physicians often have questions regarding the effect of inflammatory bowel disease on a woman's ability to conceive and to carry a pregnancy safely to term as well as the effect of inflammatory bowel disease and the medications used to treat it on pregnancy outcomes. Women with inflammatory bowel disease have the same rates of fertility as women without inflammatory bowel disease unless they have had prior surgery in the pelvis or active disease. However, women with inflammatory bowel disease do have higher rates of adverse pregnancy outcomes. A multidisciplinary approach involving gastroenterologists, obstetricians, and maternal-fetal medicine physicians should focus on preconception planning and disease optimization before pregnancy. Women with inflammatory bowel disease should be followed as high-risk obstetric patients. Most medications used to treat inflammatory bowel disease can be continued safely during pregnancy and lactation. The greatest risk to the pregnancy is active disease, which can be precipitated by discontinuation of effective maintenance medications. Preconception counseling should include education regarding the low risk of most inflammatory bowel disease medications during pregnancy and lactation and the high risk of a significant disease flare during pregnancy. This review outlines important considerations for obstetricians caring for women with inflammatory bowel disease before and during pregnancy and in the postpartum period.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26241432     DOI: 10.1097/AOG.0000000000000978

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  9 in total

1.  Antenatal Management for Women with Inflammatory Bowel Disease: Experience from Our 'IBD MOM' Clinic.

Authors:  Ariella Bar-Gil Shitrit; Yael Cohen; Ori Hassin; Ami Ben Ya'acov; Rivkah Farkash; Benjamin Koslowsky; Yael Milgrom; Dan Meir Livovsky; Arnon Samueloff; Eran Goldin; Sorina Grisaru-Granovsky
Journal:  Dig Dis Sci       Date:  2018-04-06       Impact factor: 3.199

2.  Crohn's disease: First diagnosis in pregnancy and management.

Authors:  C Jamieson; M Morosan; M Cameron
Journal:  Obstet Med       Date:  2016-10-12

3.  Ovarian reserve and IVF outcomes in patients with inflammatory bowel disease: A systematic review and meta-analysis.

Authors:  Honghao Sun; Jiao Jiao; Feng Tian; Qing Liu; Jiansu Bian; Rongmin Xu; Da Li; Xiuxia Wang; Hong Shu
Journal:  EClinicalMedicine       Date:  2022-07-01

4.  Non-communicable diseases and maternal health: a scoping review.

Authors:  Tabassum Firoz; Beth Pineles; Nishika Navrange; Alyssa Grimshaw; Olufemi Oladapo; Doris Chou
Journal:  BMC Pregnancy Childbirth       Date:  2022-10-22       Impact factor: 3.105

5.  Fertility and Contraception in Women With Inflammatory Bowel Disease.

Authors:  Jason Martin; Sunanda V Kane; Linda A Feagins
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-02

6.  Concerns in pregnancy and childbirth of women with inflammatory bowel disease.

Authors:  Sung-Ae Jung
Journal:  Intest Res       Date:  2016-04-27

7.  Optimizing Inflammatory Bowel Disease for Successful In Vitro Fertilization.

Authors:  Jason J Pan; Mora Cannon; Edward Kane; Gauree Konijeti
Journal:  ACG Case Rep J       Date:  2016-12-21

8.  Adverse Pregnancy Outcomes Following Exposure to Biologics in Women With Crohn's Disease: A Systematic Review and Meta-Analysis.

Authors:  Han Wang; Fang Chen; Yue Hu; Mengdie Shen
Journal:  Front Med (Lausanne)       Date:  2021-10-25

9.  What factors could influence physicians' management of women of childbearing age with chronic inflammatory disease? A systematic review of behavioural determinants of clinical inertia.

Authors:  Catherine Nelson-Piercy; Ivo Vlaev; Katie Harris; Rebecca Fischer-Betz
Journal:  BMC Health Serv Res       Date:  2019-11-21       Impact factor: 2.655

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.